United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from Underperform to Neutral. As of April 2, 2025, the average one-year ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

On Monday, BofA Securities analyst Greg Harrison upgraded United Therapeutics Corporation (NASDAQ:UTHR) from Underperform to Neutral, setting a price target of $314.00 for the company’s shares.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, UTHR should be on investors' short list. Should You Invest in United Therapeutics Corporation (UTHR)? Before you invest in United ...

Intrinsic value calculations suggest UTHR is undervalued, with the Graham's Formula value of $396.49 and DCF value of $370.43, averaging to $382.46. United Therapeutics (UTHR), is a company that ...

Read Our Latest Stock Report on UTHR United Therapeutics Stock Performance NASDAQ:UTHR opened at $281.16 on Monday. The stock has a market capitalization of $12.63 billion, a P/E ratio of 12.35, a ...